Previous close | 33.44 |
Open | 32.50 |
Bid | 31.62 x N/A |
Ask | 32.02 x N/A |
Day's range | 32.50 - 32.50 |
52-week range | 26.06 - 43.90 |
Volume | |
Avg. volume | 5 |
Market cap | 567.645M |
Beta (5Y monthly) | -0.01 |
PE ratio (TTM) | 295.45 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.65 (1.94%) |
Ex-dividend date | 12 June 2024 |
1y target est | N/A |
PharmaMar (MSE: PHM), world leader in the discovery, development and commercialization of marine-derived cancer treatments, presented data from a Phase II trial evaluating PharmaMar's lurbinectedin in combination with irinotecan in patients with relapsed Small Cell Lung Cancer (SCLC) after prior platinum-based treatment at the American Society of Clinical Oncology (ASCO) meeting, which took place from 31st May to 4th June in Chicago, United States.